ARPC4

Across TCGA pan-cancer cohorts, ARPC4 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARPC4 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARPC4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARPC4 expression acts as an unfavorable survival marker.

LUAD, COAD, and GBM are the cancer types where ARPC4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	III,IV	0.202	0.840	.001	29	view →
COAD	DFS	Median	IV	0.565	1.000	.028	12	view →
GBM	DFS	Median	All	0.295	0.450	.008	12	view →
HNSC	DFS	Median	II,III,IV	0.897	0.991	.004	4	view →
CCRCC	OS	Median	All	0.765	0.916	.029	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARPC4–LUAD (OS)

Open the LUAD breakdown →